2023 Fiscal Year Final Research Report
Different roles of C/EBP-alpha in chromosome conformation during lung injury of young and old mice
Project/Area Number |
21K16142
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 53030:Respiratory medicine-related
|
Research Institution | Kanazawa University (2023) Kyoto University (2021) |
Principal Investigator |
|
Project Period (FY) |
2021-04-01 – 2024-03-31
|
Keywords | C/EBP-alpha / CXCL13 / Super-enhancer / p53 / CXCR5 |
Outline of Final Research Achievements |
As per the cancer genome atlas, the C/EBP-alpha in amplified and over expressed in many cancers. Hydroxyurea (HU) treatment of lung adenocarcinoma A549 cells exhibited C/EBP-alpha's role in promoting the cell viability, suggesting the role of C/EBP-alpha in chemotherapeutic resistance. Ongoing RNA-sequencing of HU-treated 293T cells aims to identify C/EBP-alpha induced genes vital for cell survival. This will allow identifying novel therapeutic targets for treatment of C/EBP-alpha overexpressing cancers. A parallel investigation also uncovered a super enhancer region driving aberrant CXCL13 expression in human cancers. The autocrine signaling in CXCR5-CXCL13 amplified cancers can lead to chemotherapeutic resistance. Several p53 target genes were down regulated by CXCR5-CXCL13 axis in human cancer cells of B-lymphoma origin, Colorectal cancer origin and liver cancer origin. This research identified CXCR5-CXCL13 axis as a new target to overcome the chemotherapeutic resistance in cancer.
|
Free Research Field |
Epigenetics, Chromosome Conformation
|
Academic Significance and Societal Importance of the Research Achievements |
This study explores the role of C/EBP-alpha in cell survival, chemotherapeutic resistance under the DNA-replication stress. The study also explores the mechanism underlying aberrant CXCL13 expression in human cancers. Both findings offer insights into therapeutic avenues for combating human cancers.
|